©
Kaitlyn Purdie, Biophysical Immunology Laboratory, University of Oxford
The Oxford-ZEISS Centre of Excellence in Biomedical Imaging (Oxford-ZEISS CoE) and ZEISS have entered a proof-of-principle stage in the product development of a new cutting-edge imaging technology, capable of systematically measuring the behaviour of drugs in cells and tissues, which has the potential to revolutionise the testing of new medicines for safety and effectiveness.
In the 12-month proof-of-principle phase, the Oxford-ZEISS CoE and ZEISS R&D will be joined by three partners from academia and three partners from the pharmaceutical industry to test the drug-profiling applications of the innovative Selective Plane Illumination Lattice Light Sheet Microscopy (SPI LLSM) technology in cells, organoids and tissue biopsies.
The state-of-the-art SPI LLSM method uses ultrathin, non-diffracting light sheets to visualise drug interactions within 3D cell culture models and was patented by the Oxford-ZEISS CoE and ZEISS through Oxford University Innovation (OUI).
The novel technique was developed at the Oxford-ZEISS CoE as a solution to the limitations of existing imaging methods, such as fluorescence correlation spectroscopy (FCS), to address the need for a fast, reliable, and high-resolution technology that can measure and characterise how drugs behave in standardised biological models.
Read the full story on the Institute of Developmental & Regenerative Medicine website.